阳光诺和收购朗研生命再折戟

Core Viewpoint - Sunshine Nuohong's acquisition of Jiangsu Langyan Life Science Technology Co., Ltd. has been terminated due to changes in the market environment, marking the second failed attempt since 2022 [1][3][5] Group 1: Acquisition Details - On January 28, Sunshine Nuohong announced the termination of the major asset restructuring, which involved acquiring 100% of Langyan Life's shares through the issuance of shares and convertible bonds [2][4] - The restructuring process began in April 2025 and was accepted by the Shanghai Stock Exchange in November 2025 [2][5] - Langyan Life specializes in the R&D, production, and sales of high-end chemical drug formulations and raw materials, aiming to become a professional manufacturer and service provider in the pharmaceutical sector [2][5] Group 2: Financial Performance of Langyan Life - Langyan Life's revenue showed fluctuations, with reported revenues of approximately 510 million yuan and 617 million yuan for 2021 and 2022, respectively, and a decline to about 463 million yuan, 415 million yuan, and 231 million yuan for 2023, 2024, and the first half of 2025 [5] - Corresponding net profits were approximately 37.54 million yuan and 85.13 million yuan for 2021 and 2022, with a decrease to around 32.15 million yuan, 55.21 million yuan, and 48.75 million yuan for the subsequent years [5] Group 3: Reasons for Termination - The termination was attributed to changes in the market environment and the need to protect the interests of the company and its shareholders, as stated by the board of directors [3][6] - The company did not respond to the Shanghai Stock Exchange's inquiry letter within the required timeframe, leading to the decision to terminate the transaction [7][8] - The challenges faced during the acquisition process reflect the complexities of executing asset restructurings in the biopharmaceutical industry, including valuation uncertainties and strict regulatory scrutiny [6][8]